Cencora Inc. ($COR) Stock Forecast: Up 5.1% Today

What is Cencora Inc.?

Cencora Inc. (NYSE: COR) is a global pharmaceutical services company with a market cap of approximately $65.7 billion. The company has been making strategic moves in the healthcare distribution sector, focusing on specialty services and technology solutions.

Why is Cencora Inc. going up?

COR stock is up 5.1% on Jan 6, 2026 15:16

• The bullish movement in Cencora's stock today can be attributed to the strong fiscal second-quarter results from a key player in the pharmaceutical distribution industry.
• Impressive earnings momentum from specialty and automation services in the sector has likely boosted investor confidence industry-wide, including companies like Cencora.
• Concerns raised about Cencora's valuation and lowered price target have been overshadowed by the overall positive outlook for the company, particularly with its recent acquisition and growth targets.
• The increasing interest from institutional investors and hedge funds in Cencora, as noted in the ownership structure, indicates growing confidence in the company's future prospects, contributing to the bullish trend observed today.

COR Price Chart

COR Technical Analysis

COR News

McKesson Builds Earnings Momentum on Specialty and Automation

McKesson delivered a strong fiscal second quarter with consolidated revenues of $103 billion, up 10% year-over-year, and adjusted earnings per diluted share rising 39% to $9.86, leading management to raise full-year guidance. The company’s growth is driven by its North American Pharmaceutical distribution, accelerating specialty volumes, and rising contributions from prescription technology services, particularly within oncology and multispecialty segments. McKesson's long-term strategy focuses on scaling differentiated specialty platforms, leveraging technology and automation for efficiency, and expanding its presence in the biopharma and provider ecosystem.

https://www.tradingview.com/news/zacks:467840458094b:0-mckesson-builds-earnings-momentum-on-specialty-and-automation/

Who Owns Cencora? Top Shareholders and Recent Insider Activity

Cencora Inc. (NYSE: COR) is a global pharmaceutical services company with a market cap of approximately $65.7 billion. Its ownership is dominated by large institutional investors like The Vanguard Group and BlackRock, with hedge funds also increasing their positions. Recent insider transactions have been minor and appear to be personal portfolio management rather than signals of significant changes in company outlook.

https://www.tikr.com/pt/blog/who-owns-cencora-top-shareholders-and-recent-insider-activity?ref=tikrblog

McKesson Corporation: How a Quiet Infrastructure Giant Is Rewiring Healthcare Distribution

McKesson Corporation is transforming from a traditional drug wholesaler into a data-driven healthcare infrastructure platform, leveraging technology, scale, and an extensive ecosystem. This strategic shift involves moving beyond mere distribution to providing critical infrastructure for modern healthcare, highlighted by its focus on specialty and oncology services, alongside comprehensive technology and data solutions. The company's unique approach, combining massive scale with specialization and ecosystem neutrality, positions it as an indispensable partner across the healthcare value chain, driving investor enthusiasm for McKesson Aktie.

https://www.ad-hoc-news.de/boerse/news/ueberblick/mckesson-corporation-how-a-quiet-infrastructure-giant-is-rewiring/68461600

Cencora stock price target lowered to $360 by BofA on valuation concerns

BofA Securities has lowered its price target for Cencora Inc. (NYSE:COR) to $360 from $380, maintaining a Neutral rating due to valuation concerns, despite the company's strong long-term outlook. The adjustment reflects a contraction in peer multiples and the stock currently trading at a premium relative to its growth rate, according to InvestingPro metrics. This contrasts with several other firms like Evercore ISI, TD Cowen, UBS, and Leerink Partners, which recently raised their price targets for Cencora following its acquisition announcement of OneOncology and positive guidance.

https://au.investing.com/news/analyst-ratings/cencora-stock-price-target-lowered-to-360-by-bofa-on-valuation-concerns-93CH-4191225

Cencora stock price target lowered to $360 by BofA on valuation concerns

BofA Securities has lowered its price target for Cencora Inc (NYSE:COR) to $360 from $380, citing valuation concerns despite the company's strong long-term outlook. This adjustment comes after Cencora recently raised its long-term growth targets and announced a major acquisition, leading other analysts to increase their price targets. The firm highlighted Cencora's high P/E and PEG ratios as indicators that its current stock price already reflects significant future growth.

https://uk.investing.com/news/analyst-ratings/cencora-stock-price-target-lowered-to-360-by-bofa-on-valuation-concerns-93CH-4437975

Trending Today

Jupiter ($JUP) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Down 6.0% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

Gold ($XAU) Commodity Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Revvity ($RVTY) Stock Forecast: Down 5.3% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.1% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Down 6.1% Today

Cencora Inc. Price History

23.08.2025 - COR Stock was up 5.1%

• The strong bullish movement in Cencora (NYSE: COR) today may be linked to its impressive long-term outperformance of the market, boasting an average annual return of 20.51% over the past decade.
• Investors seem to be drawn to COR because of its consistent growth and its ability to produce returns that surpass the market average significantly.
• The coverage of COR's exceptional performance in recent times could have further piqued investor interest, leading to an increase in the stock price.

06.00.2026 - COR Stock was up 5.1%

• The bullish movement in Cencora's stock today can be attributed to the strong fiscal second-quarter results from a key player in the pharmaceutical distribution industry.
• Impressive earnings momentum from specialty and automation services in the sector has likely boosted investor confidence industry-wide, including companies like Cencora.
• Concerns raised about Cencora's valuation and lowered price target have been overshadowed by the overall positive outlook for the company, particularly with its recent acquisition and growth targets.
• The increasing interest from institutional investors and hedge funds in Cencora, as noted in the ownership structure, indicates growing confidence in the company's future prospects, contributing to the bullish trend observed today.

08.04.2025 - COR Stock was down 4.2%

• Despite surpassing Q2 earnings and revenue estimates, COR witnessed a bearish movement in the market.
• Concerns about revenue sustainability and competition in the pharmaceutical sector may have contributed to the market's negative reaction.
• Investor caution regarding the company's growth sustainability could result in profit-taking and a bearish stock price trend.
• Broader economic factors and sector-specific challenges in the pharmaceutical industry might also influence the market movement.

08.04.2025 - COR Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue expectations, COR observed a decline in its stock price today.
• The high demand for weight loss drugs and specialty products might not have sustained the stock's elevated value, resulting in profit-taking by traders.
• The market's response could be due to concerns regarding future growth prospects or uncertainties about the company's trajectory.
• Investors may have anticipated stronger results or guidance from COR, triggering a stock sell-off despite its recent accomplishments in the healthcare solutions industry.

05.00.2026 - COR Stock was down 0.6%

• A notable adjustment was made to COR's price target by B of A Securities, lowering it from $380.00 to $360.00. This change, amidst other analysts raising their targets, may have contributed to the bearish movement.
• Institutional confidence in COR was highlighted when Gateway Investment Advisers LLC significantly increased its stake in the company by 1,135.4% to $37.23 million. However, recent insider selling activities may have raised concerns among investors.
• Comments on COR's strong fundamentals, resilient earnings, and strategic focus on specialty distribution and biosimilars have surfaced, suggesting a positive outlook. This implies that the bearish movement could be a temporary correction rather than an indicator of the company's long-term potential.
• The market movements observed today regarding COR could be explained by short-term price adjustments resulting from conflicting analyst opinions and profit-taking behaviors following a period of consistent value appreciation.

15.08.2025 - COR Stock was down 1.9%

• The factors behind the bearish movement in COR include:
• Investors taking profits following a recent uptrend.
• Worries about decreased demand for cloud computing services.
• Negative impact of overall market sentiment on tech stocks.
• Absence of specific positive news or catalysts to drive buying activity for COR.

05.10.2025 - COR Stock was down 0.1%

• Despite Cencora (COR) surpassing earnings and revenue estimates for Q4, the stock exhibited bearish movement.
• Investors may have had higher expectations or anticipated growth projections beyond the reported numbers, resulting in a sell-off.
• Market sentiment could have been swayed by external factors such as macroeconomic uncertainties or industry shifts, rather than the company's financial achievements.
• Some investors might have opted to take profits after the positive news, leading to a temporary decline in the stock price.

07.04.2025 - COR Stock was up 5.7%

• COR outperformed Q2 earnings and revenue expectations, signaling robust financial results.
• The U.S. Healthcare Solutions segment's favorable outlook is anticipated to be a key driver of COR's success.
• Analysts hold a positive view on COR's crucial metrics for the quarter, indicating a favorable path for the company.
• Investors reacted favorably to the strong performance and growth potential of COR, leading to the uptrend in the stock price.

16.11.2025 - COR Stock was down 2.4%

• Factors contributing to the bearish movement in Cencora's stock (COR) today include:
• Concerns over the significant financial commitment of $5 billion for the OneOncology acquisition, impacting immediate financials.
• Investor caution regarding the initial EPS neutrality and timeline for positive contribution from the deal by mid-fiscal year 2027, despite positive analyst sentiment and raised price targets post-acquisition.
• Influence of recent market fluctuations and economic data on broader market sentiment, potentially affecting COR stock movement.
• Investor hesitancy as they wait to see the ultimate impact of OneOncology acquisition on Cencora's market position and financial performance, resulting in a temporary decline in stock price.

06.07.2025 - COR Stock was down 6.4%

• The bearish movement in COR stock today may be linked to the market's reaction to the company's Q3 earnings, despite exceeding earnings and revenue expectations. Here's a breakdown of the situation:
• The market could have anticipated more robust results given COR's consistent outperformance, leading to a sell-off.
• Worries about international challenges impacting Q3 figures might have unsettled investors, overshadowing the positive earnings beats.
• Investors expecting a significant earnings beat based on Wall Street projections might have felt let down, resulting in a decline in the stock's value.
• While hopes were high for COR's earnings growth, the market's response today indicates that even surpassing estimates does not always guarantee a positive reaction from investors.

04.03.2025 - COR Stock was down 0.7%

• Despite being considered a safe bet during market volatility, COR faced a strong bearish movement today.
• The comparison with other medical stocks like Intensity Therapeutics Inc. may have highlighted weaknesses in COR's performance, contributing to the bearish trend.
• The overall market volatility, potentially influenced by external factors, could have also played a role in the bearish movement of COR today.

31.06.2025 - COR Stock was down 2.4%

• The decline in COR's stock today could be due to profit-taking by investors who were possibly anticipating a positive earnings outcome.
• Comparisons with McKesson (MCK) in the medical sector may have impacted investor sentiment, resulting in a sell-off of COR as it might have shown lower performance compared to its sector so far this year.
• Investors might be reassessing their holdings in COR based on its performance relative to McKesson, potentially influencing the downward trend in the stock.